DNCP-β-NalA

DNCP-β-NalA is an experimental peptide-drug conjugate (PDC) designed as a potent agonist of the **kappa opioid receptor (KOR)**. It is being investigated for its potential to treat severe abdominal pain associated with **inflammatory bowel disease (IBD)** by leveraging the analgesic and anti-inflammatory effects of KOR activation. The compound acts as a full agonist for the Gαi signaling pathway (pEC50 = 9.6 in wildtype KOR) and exhibits a specific signaling profile regarding β-arrestin recruitment. Research into DNCP-β-NalA has highlighted how specific KOR mutations (such as E209A and Y312A) can alter its efficacy and signaling bias, providing insights into the molecular pharmacology of KOR-targeted therapies for visceral pain.